Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis.

Nguyen DX, Cotton A, Attipoe L, Ciurtin C, Doré CJ, Ehrenstein MR.

J Allergy Clin Immunol. 2018 Sep;142(3):978-980.e9. doi: 10.1016/j.jaci.2018.04.026. Epub 2018 Jun 20. No abstract available.

2.

Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT.

Gilbert RM, Zhang X, Sampson RD, Ehrenstein MR, Nguyen DX, Chaudhry M, Mein C, Mahmud N, Galatowicz G, Tomkins-Netzer O, Calder VL, Lightman S.

Front Immunol. 2018 May 3;9:907. doi: 10.3389/fimmu.2018.00907. eCollection 2018.

3.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
4.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

5.

CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22.

Ezeonyeji A, Baldwin H, Vukmanovic-Stejic M, Ehrenstein MR.

Front Immunol. 2017 Oct 27;8:1403. doi: 10.3389/fimmu.2017.01403. eCollection 2017.

6.

Tumor Necrosis Factor (TNF) Bioactivity at the Site of an Acute Cell-Mediated Immune Response Is Preserved in Rheumatoid Arthritis Patients Responding to Anti-TNF Therapy.

Byng-Maddick R, Turner CT, Pollara G, Ellis M, Guppy NJ, Bell LCK, Ehrenstein MR, Noursadeghi M.

Front Immunol. 2017 Aug 4;8:932. doi: 10.3389/fimmu.2017.00932. eCollection 2017.

7.

DNA methylation governs the dynamic regulation of inflammation by apoptotic cells during efferocytosis.

Notley CA, Jordan CK, McGovern JL, Brown MA, Ehrenstein MR.

Sci Rep. 2017 Feb 7;7:42204. doi: 10.1038/srep42204.

8.

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.

Nguyen DX, Ehrenstein MR.

J Exp Med. 2016 Jun 27;213(7):1241-53. doi: 10.1084/jem.20151255. Epub 2016 Jun 6.

9.

The BAFFling effects of rituximab in lupus: danger ahead?

Ehrenstein MR, Wing C.

Nat Rev Rheumatol. 2016 Jun;12(6):367-72. doi: 10.1038/nrrheum.2016.18. Epub 2016 Feb 18. Review.

PMID:
26888554
10.

Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production.

Chavele KM, Merry E, Ehrenstein MR.

J Immunol. 2015 Mar 15;194(6):2482-5. doi: 10.4049/jimmunol.1401190. Epub 2015 Feb 13.

11.

The impact of biological therapy on regulatory T cells in rheumatoid arthritis.

Byng-Maddick R, Ehrenstein MR.

Rheumatology (Oxford). 2015 May;54(5):768-75. doi: 10.1093/rheumatology/keu487. Epub 2015 Feb 8. Review.

PMID:
25667434
12.

Engulfment of activated apoptotic cells abolishes TGF-β-mediated immunoregulation via the induction of IL-6.

Notley CA, Brown MA, McGovern JL, Jordan CK, Ehrenstein MR.

J Immunol. 2015 Feb 15;194(4):1621-7. doi: 10.4049/jimmunol.1401256. Epub 2015 Jan 19.

13.

Induced CD8+FoxP3+ Treg cells in rheumatoid arthritis are modulated by p38 phosphorylation and monocytes expressing membrane tumor necrosis factor α and CD86.

Ellis SD, McGovern JL, van Maurik A, Howe D, Ehrenstein MR, Notley CA.

Arthritis Rheumatol. 2014 Oct;66(10):2694-705. doi: 10.1002/art.38761.

14.

B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis.

Rapetti L, Chavele KM, Evans CM, Ehrenstein MR.

Ann Rheum Dis. 2015 Jan;74(1):294-302. doi: 10.1136/annrheumdis-2013-204049. Epub 2013 Nov 18.

PMID:
24249811
15.
16.

CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation.

Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, Mauri C.

Sci Transl Med. 2013 Feb 20;5(173):173ra23. doi: 10.1126/scitranslmed.3005407.

17.

Germinal center B cells govern their own fate via antibody feedback.

Zhang Y, Meyer-Hermann M, George LA, Figge MT, Khan M, Goodall M, Young SP, Reynolds A, Falciani F, Waisman A, Notley CA, Ehrenstein MR, Kosco-Vilbois M, Toellner KM.

J Exp Med. 2013 Mar 11;210(3):457-64. doi: 10.1084/jem.20120150. Epub 2013 Feb 18.

18.

Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.

McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR.

Arthritis Rheum. 2012 Oct;64(10):3129-38. doi: 10.1002/art.34565.

19.

B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels.

Lazarus MN, Turner-Stokes T, Chavele KM, Isenberg DA, Ehrenstein MR.

Rheumatology (Oxford). 2012 Jul;51(7):1208-15. doi: 10.1093/rheumatology/ker526. Epub 2012 Feb 15.

20.

Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance.

Chiu Y, Ostor AJ, Hammond A, Sokoll K, Anderson M, Buch M, Ehrenstein MR, Gordon P, Steer S, Bruce IN.

Clin Rheumatol. 2012 Jun;31(6):1005-12. doi: 10.1007/s10067-011-1936-6. Epub 2012 Jan 25.

21.

A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide.

Gupta RK, Ezeonyeji AN, Thomas AS, Scully MA, Ehrenstein MR, Isenberg DA.

Lupus. 2011 Dec;20(14):1547-50. doi: 10.1177/0961203311411349. Epub 2011 Oct 12.

PMID:
21993386
22.

Therapeutic potential of Tregs to treat rheumatoid arthritis.

Wright GP, Stauss HJ, Ehrenstein MR.

Semin Immunol. 2011 Jun;23(3):195-201. doi: 10.1016/j.smim.2011.07.004. Epub 2011 Aug 30. Review.

PMID:
21880506
23.

Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis.

Chavele KM, Ehrenstein MR.

FEBS Lett. 2011 Dec 1;585(23):3603-10. doi: 10.1016/j.febslet.2011.07.043. Epub 2011 Aug 4. Review.

24.

Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells.

Carter NA, Vasconcellos R, Rosser EC, Tulone C, Muñoz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C.

J Immunol. 2011 May 15;186(10):5569-79. doi: 10.4049/jimmunol.1100284. Epub 2011 Apr 4.

25.

Regulatory T-cell adoptive immunotherapy: potential for treatment of autoimmunity.

Wright GP, Ehrenstein MR, Stauss HJ.

Expert Rev Clin Immunol. 2011 Mar;7(2):213-25. doi: 10.1586/eci.10.96. Review.

PMID:
21426259
26.

The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation.

Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA.

Rheumatology (Oxford). 2011 Aug;50(8):1401-8. doi: 10.1093/rheumatology/ker018. Epub 2011 Mar 12.

PMID:
21398661
27.

Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells.

Notley CA, Brown MA, Wright GP, Ehrenstein MR.

J Immunol. 2011 Apr 15;186(8):4967-72. doi: 10.4049/jimmunol.1003021. Epub 2011 Mar 7.

28.

Tuberculosis and anti-TNF treatment: experience of a central London hospital.

Mankia S, Peters JE, Kang S, Moore S, Ehrenstein MR.

Clin Rheumatol. 2011 Mar;30(3):399-401. doi: 10.1007/s10067-010-1605-1. Epub 2010 Oct 23.

PMID:
20972591
29.

Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis.

Arce F, Breckpot K, Stephenson H, Karwacz K, Ehrenstein MR, Collins M, Escors D.

Arthritis Rheum. 2011 Jan;63(1):84-95. doi: 10.1002/art.30099.

30.

The importance of natural IgM: scavenger, protector and regulator.

Ehrenstein MR, Notley CA.

Nat Rev Immunol. 2010 Nov;10(11):778-86. doi: 10.1038/nri2849. Epub 2010 Oct 15. Review.

PMID:
20948548
31.

The yin and yang of regulatory T cells and inflammation in RA.

Notley CA, Ehrenstein MR.

Nat Rev Rheumatol. 2010 Oct;6(10):572-7. doi: 10.1038/nrrheum.2010.143. Epub 2010 Aug 31. Review.

PMID:
20808295
32.

Secreted IgM enhances B cell receptor signaling and promotes splenic but impairs peritoneal B cell survival.

Notley CA, Baker N, Ehrenstein MR.

J Immunol. 2010 Apr 1;184(7):3386-93. doi: 10.4049/jimmunol.0902640. Epub 2010 Mar 5.

33.

CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C.

Immunity. 2010 Jan 29;32(1):129-40. doi: 10.1016/j.immuni.2009.11.009. Epub 2010 Jan 14.

34.

Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus.

Jury EC, Flores-Borja F, Kalsi HS, Lazarus M, Isenberg DA, Mauri C, Ehrenstein MR.

Eur J Immunol. 2010 Feb;40(2):569-78. doi: 10.1002/eji.200939781.

35.

Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis.

Wright GP, Notley CA, Xue SA, Bendle GM, Holler A, Schumacher TN, Ehrenstein MR, Stauss HJ.

Proc Natl Acad Sci U S A. 2009 Nov 10;106(45):19078-83. doi: 10.1073/pnas.0907396106. Epub 2009 Nov 2.

36.

Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice.

Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO.

Circulation. 2009 Aug 4;120(5):417-26. doi: 10.1161/CIRCULATIONAHA.109.868158. Epub 2009 Jul 20.

37.

Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice.

Blair PA, Chavez-Rueda KA, Evans JG, Shlomchik MJ, Eddaoudi A, Isenberg DA, Ehrenstein MR, Mauri C.

J Immunol. 2009 Mar 15;182(6):3492-3502. doi: 10.4049/jimmunol.0803052.

38.

Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.

Flores-Borja F, Jury EC, Mauri C, Ehrenstein MR.

Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19396-401. doi: 10.1073/pnas.0806855105. Epub 2008 Nov 26.

39.

Restoring the balance: harnessing regulatory T cells for therapy in rheumatoid arthritis.

Flores-Borja F, Mauri C, Ehrenstein MR.

Eur J Immunol. 2008 Apr;38(4):934-7. doi: 10.1002/eji.200738107.

40.

Antibodies and other biomarkers - pathological consequences (2).

Ehrenstein MR, Alves JD.

Lupus. 2008 Mar;17(3):256-8. doi: 10.1177/0961203307088253. No abstract available.

PMID:
18372372
41.

The 'short' history of regulatory B cells.

Mauri C, Ehrenstein MR.

Trends Immunol. 2008 Jan;29(1):34-40. doi: 10.1016/j.it.2007.10.004. Epub 2007 Dec 3. Review.

PMID:
18289504
42.

If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine.

Ehrenstein MR, Mauri C.

J Exp Med. 2007 Oct 1;204(10):2249-52. Epub 2007 Sep 24.

43.

Novel suppressive function of transitional 2 B cells in experimental arthritis.

Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, Mauri C.

J Immunol. 2007 Jun 15;178(12):7868-78.

44.

Fifty years of anti-ds DNA antibodies: are we approaching journey's end?

Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A.

Rheumatology (Oxford). 2007 Jul;46(7):1052-6. Epub 2007 May 11. Review.

PMID:
17500073
45.

Cells of the synovium in rheumatoid arthritis. B cells.

Mauri C, Ehrenstein MR.

Arthritis Res Ther. 2007;9(2):205. Review.

46.

B cell depletion in systemic lupus erythematosus.

Leandro MJ, Ehrenstein MR.

Clin Med (Lond). 2007 Jan-Feb;7(1):57-9. Review. No abstract available.

47.

Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice.

Ferry H, Potter PK, Crockford TL, Nijnik A, Ehrenstein MR, Walport MJ, Botto M, Cornall RJ.

J Immunol. 2007 Mar 1;178(5):2916-22.

48.

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta.

Nadkarni S, Mauri C, Ehrenstein MR.

J Exp Med. 2007 Jan 22;204(1):33-9. Epub 2007 Jan 2. Erratum in: J Exp Med. 2007 Jan 22;204(1):205.

49.
50.

Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.

Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC.

Rheumatology (Oxford). 2007 Jan;46(1):29-36. Epub 2006 May 30.

PMID:
16735454

Supplemental Content

Loading ...
Support Center